Location History:
- Hanover, NH (US) (2014 - 2015)
- White River Junction, VT (US) (2020)
- Lebanon, NH (US) (2016 - 2024)
Company Filing History:
Years Active: 2014-2024
Title: **Mark R. Spaller: Innovator in Cancer Treatment and Infections**
Introduction
Mark R. Spaller is a prominent inventor based in White River Junction, VT, known for his significant contributions in the field of biomedical research. With a total of 8 patents to his name, his work focuses on developing therapeutic methods to combat various health challenges, particularly in cancer and infectious diseases.
Latest Patents
Among his most notable inventions is the "VISTA antagonist and methods of use." This invention is centered around a peptide, multimer, conjugate, analog, derivative, or mimetic that inhibits the activity of VISTA. The therapeutic applications of this VISTA antagonist extend to treating or preventing cancer, bacterial infections, viral infections, parasitic infections, and fungal infections. This innovation not only aims to provide clinical solutions but also supports research applications in understanding the antagonist's full potential.
Career Highlights
Mark R. Spaller has had an impactful career, contributing to major research institutions such as Dartmouth College and the Mayo Foundation for Medical Education and Research. His academic endeavors and inventive spirit have led to advancements that hold promise for future medical treatments.
Collaborations
Throughout his career, Mark has collaborated with notable individuals in the research community, including Randolph J. Noelle and Sabrina Ceeraz. These partnerships signify the collaborative nature of scientific innovation and highlight the importance of teamwork in achieving groundbreaking results.
Conclusion
Mark R. Spaller's contributions to the field of biomedical research through his patents and collaborations underscore the critical role of innovation in healthcare. His work continues to inspire upcoming inventors and researchers dedicated to tackling significant health issues.